EHD2 overexpression promotes tumorigenesis and metastasis in triple-negative breast cancer by regulating store-operated calcium entry

Abstract

With nearly all cancer deaths a result of metastasis, elucidating novel pro-metastatic cellular adaptations could provide new therapeutic targets. Here, we show that overexpression of the EPS15-Homology Domain-containing 2 (EHD2) protein in a large subset of breast cancers (BCs), especially the triple-negative (TNBC) and HER2+ subtypes, correlates with shorter patient survival. The mRNAs for EHD2 and Caveolin-1/2, structural components of caveolae, show co-overexpression across breast tumors, predicting shorter survival in basal-like BC. EHD2 shRNA knockdown and CRISPR-Cas9 knockout with mouse Ehd2 rescue, in TNBC cell line models demonstrate a major positive role of EHD2 in promoting tumorigenesis and metastasis. Mechanistically, we link these roles of EHD2 to store-operated calcium entry (SOCE), with EHD2-dependent stabilization of plasma membrane caveolae ensuring high cell surface expression of the SOCE-linked calcium channel Orai1. The novel EHD2-SOCE oncogenic axis represents a potential therapeutic target in EHD2 and CAV1/2-overexpressing BC.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting file.

Article and author information

Author details

  1. Haitao Luan

    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  2. Timothy A Bielecki

    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  3. Bhopal C Mohapatra

    Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  4. Namista Islam

    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  5. Insha Mushtaq

    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  6. Aaqib M Bhat

    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  7. Sameer Mirza

    Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  8. Sukanya Chakraborty

    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  9. Mohsin Raza

    Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  10. Matthew D Storck

    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  11. Michael S Toss

    Department of Histopathology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
    Competing interests
    No competing interests declared.
  12. Jane L Meza

    Departments of Biostatistics, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  13. Wallace B Thoreson

    Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7104-042X
  14. Donald W Coulter

    Department of Pediatrics, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  15. Emad A Rakha

    Department of Histopathology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
    Competing interests
    No competing interests declared.
  16. Vimla Band

    Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, United States
    For correspondence
    vband@unmc.edu
    Competing interests
    Vimla Band, received funding from Nimbus Therapeutics for an unrelated project..
  17. Hamid Band

    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, United States
    For correspondence
    hband@unmc.edu
    Competing interests
    Hamid Band, received funding from Nimbus Therapeutics for an unrelated project..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4996-9002

Funding

Department of Defence (W81XWH-17-1-0616 and W81XWH-20-1-0058)

  • Hamid Band

Department of Defence (W81XWH-20-1-0546)

  • Vimla Band

National Institutes of Health (R21CA241055 and R03CA253193)

  • Vimla Band

Fred and Pamela Buffett Cancer Center (Pilot grant)

  • Vimla Band

Fred and Pamela Buffett Cancer Center (Pilot grant)

  • Hamid Band

University of Nebraska Medical Center (Graduate Student Fellowships)

  • Timothy A Bielecki

University of Nebraska Medical Center (Graduate Student Fellowships)

  • Aaqib M Bhat

University of Nebraska Medical Center (Graduate Student Fellowships)

  • Sukanya Chakraborty

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Jonathan A Cooper, Fred Hutchinson Cancer Center, United States

Ethics

Animal experimentation: All mouse xenograft and treatment studies were pre-approved by the UNMC Institutional Animal Care and Use Committee (IACUC) under the IACUC protocol number 19-115-10-FC and conducted strictly according to the pre-approved procedures, in compliance with Federal and State guidelines.

Human subjects: Human tissues were collected and processed at the Nottingham University Hospital, United Kingdom. This study was approved by the Yorkshire & The Humber-Leeds East Research Ethics Committee (REC reference: 19/YH/0293) under the IRAS Project ID: 266925. Informed consent was obtained from all individuals prior to surgery for the use of their tissue materials in research. All samples were properly coded and anonymized in accordance with the approved protocols.

Version history

  1. Received: June 22, 2022
  2. Preprint posted: June 25, 2022 (view preprint)
  3. Accepted: January 10, 2023
  4. Accepted Manuscript published: January 10, 2023 (version 1)
  5. Version of Record published: March 6, 2023 (version 2)

Copyright

© 2023, Luan et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,207
    Page views
  • 210
    Downloads
  • 3
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Haitao Luan
  2. Timothy A Bielecki
  3. Bhopal C Mohapatra
  4. Namista Islam
  5. Insha Mushtaq
  6. Aaqib M Bhat
  7. Sameer Mirza
  8. Sukanya Chakraborty
  9. Mohsin Raza
  10. Matthew D Storck
  11. Michael S Toss
  12. Jane L Meza
  13. Wallace B Thoreson
  14. Donald W Coulter
  15. Emad A Rakha
  16. Vimla Band
  17. Hamid Band
(2023)
EHD2 overexpression promotes tumorigenesis and metastasis in triple-negative breast cancer by regulating store-operated calcium entry
eLife 12:e81288.
https://doi.org/10.7554/eLife.81288

Share this article

https://doi.org/10.7554/eLife.81288

Further reading

    1. Cancer Biology
    2. Cell Biology
    Julian J A Hoving, Elizabeth Harford-Wright ... Alison C Lloyd
    Research Article

    Collective cell migration is fundamental for the development of organisms and in the adult, for tissue regeneration and in pathological conditions such as cancer. Migration as a coherent group requires the maintenance of cell-cell interactions, while contact inhibition of locomotion (CIL), a local repulsive force, can propel the group forward. Here we show that the cell-cell interaction molecule, N-cadherin, regulates both adhesion and repulsion processes during rat Schwann cell (SC) collective migration, which is required for peripheral nerve regeneration. However, distinct from its role in cell-cell adhesion, the repulsion process is independent of N-cadherin trans-homodimerisation and the associated adherens junction complex. Rather, the extracellular domain of N-cadherin is required to present the repulsive Slit2/Slit3 signal at the cell-surface. Inhibiting Slit2/Slit3 signalling inhibits CIL and subsequently collective Schwann cell migration, resulting in adherent, nonmigratory cell clusters. Moreover, analysis of ex vivo explants from mice following sciatic nerve injury showed that inhibition of Slit2 decreased Schwann cell collective migration and increased clustering of Schwann cells within the nerve bridge. These findings provide insight into how opposing signals can mediate collective cell migration and how CIL pathways are promising targets for inhibiting pathological cell migration.

    1. Cancer Biology
    2. Structural Biology and Molecular Biophysics
    Johannes Paladini, Annalena Maier ... Stephan Grzesiek
    Research Article

    Abelson tyrosine kinase (Abl) is regulated by the arrangement of its regulatory core, consisting sequentially of the SH3, SH2, and kinase (KD) domains, where an assembled or disassembled core corresponds to low or high kinase activity, respectively. It was recently established that binding of type II ATP site inhibitors, such as imatinib, generates a force from the KD N-lobe onto the SH3 domain and in consequence disassembles the core. Here, we demonstrate that the C-terminal αI-helix exerts an additional force toward the SH2 domain, which correlates both with kinase activity and type II inhibitor-induced disassembly. The αI-helix mutation E528K, which is responsible for the ABL1 malformation syndrome, strongly activates Abl by breaking a salt bridge with the KD C-lobe and thereby increasing the force onto the SH2 domain. In contrast, the allosteric inhibitor asciminib strongly reduces Abl’s activity by fixating the αI-helix and reducing the force onto the SH2 domain. These observations are explained by a simple mechanical model of Abl activation involving forces from the KD N-lobe and the αI-helix onto the KD/SH2SH3 interface.